PERSPECTIVE THERAPEUTICS, INC. Financials Perspective Therapeutics, Inc.
Equities
CATX
US46489V1044
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.4 USD | +6.06% |
|
-6.67% | +248.26% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 42.08 | 39.25 | 55.03 | 35.12 | 112.8 | 930.3 | - | - |
| Enterprise Value (EV) 1 | 42.08 | 39.25 | 55.03 | 35.12 | 112.8 | 930.3 | 930.3 | 930.3 |
| P/E ratio | -7.81 x | -9 x | -12.9 x | -4.94 x | -2.36 x | -14 x | -12.7 x | -12.5 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 5.75 x | 4.06 x | 5.47 x | 9.89 x | 78.7 x | 1,779 x | 2,895 x | 2,214 x |
| EV / Revenue | 5.75 x | 4.06 x | 5.47 x | 9.89 x | 78.7 x | 1,779 x | 2,895 x | 2,214 x |
| EV / EBITDA | -8,302,505 x | -13,682,309 x | -19,149,179 x | - | - | - | - | - |
| EV / FCF | - | - | - | - | -2.97 x | -14.8 x | -14.1 x | -26 x |
| FCF Yield | - | - | - | - | -33.7% | -6.78% | -7.1% | -3.85% |
| Price to Book | 5.45 x | 5.42 x | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 67,388 | 87,232 | 141,915 | 142,113 | 280,571 | 674,145 | - | - |
| Reference price 2 | 0.6244 | 0.4500 | 0.3878 | 0.2471 | 0.4020 | 1.380 | 1.380 | 1.380 |
| Announcement Date | 9/24/19 | 9/17/20 | 9/21/21 | 5/1/23 | 3/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 7.314 | 9.68 | 10.05 | 3.552 | 1.434 | 0.523 | 0.3214 | 0.4202 |
| EBITDA | -5.068 | -2.869 | -2.874 | - | - | - | - | - |
| EBIT 1 | -5.254 | -3.549 | -3.446 | - | -40.94 | -56.25 | -63.86 | -68.93 |
| Operating Margin | -71.83% | -36.66% | -34.28% | - | -2,855.02% | -10,755.64% | -19,868.54% | -16,401.43% |
| Earnings before Tax (EBT) 1 | -5.144 | -3.446 | -3.387 | - | -40.11 | -54.54 | -64.26 | -68.14 |
| Net income 1 | -5.155 | -3.457 | -3.39 | - | -46.51 | -54.63 | -64.26 | -68.14 |
| Net margin | -70.48% | -35.71% | -33.72% | - | -3,243.24% | -10,444.97% | -19,994.84% | -16,214.1% |
| EPS 2 | -0.0800 | -0.0500 | -0.0300 | -0.0500 | -0.1700 | -0.0983 | -0.1083 | -0.1100 |
| Free Cash Flow 1 | - | - | - | - | -37.98 | -63.05 | -66.09 | -35.77 |
| FCF margin | - | - | - | - | -2,648.88% | -12,056.21% | -20,562.23% | -8,512.31% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 9/24/19 | 9/17/20 | 9/21/21 | 5/1/23 | 3/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2.6 | 2.71 | 2.063 | 2.088 | 1.909 | -4.902 | 0.325 | 0.0664 | 0.0676 | 0.069 | 0.107 |
| EBITDA | -0.721 | -0.916 | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -0.766 | -1.093 | - | -11.37 | -10.53 | -7.806 | -13 | -13.86 | -14.39 | -15 | -15.18 |
| Operating Margin | -29.46% | -40.33% | - | -544.73% | -551.81% | 159.24% | -4,001.54% | -20,867.47% | -21,294.01% | -21,735.14% | -14,191.12% |
| Earnings before Tax (EBT) 1 | -0.745 | -1.061 | - | -11.11 | -10.36 | -7.773 | -12.28 | -13.59 | -14 | -14.63 | -15.18 |
| Net income 1 | -0.745 | -1.061 | - | -11.11 | -10.36 | -24.68 | -12.28 | -13.59 | -14 | -14.63 | -15.18 |
| Net margin | -28.65% | -39.15% | - | -531.9% | -542.48% | 503.37% | -3,779.69% | -20,462.95% | -20,708.28% | -21,202.32% | -14,188.79% |
| EPS 2 | -0.0100 | -0.0100 | - | -0.0400 | -0.0400 | -0.0900 | -0.0200 | -0.0200 | -0.0220 | -0.0220 | -0.0250 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 5/13/21 | 9/21/21 | 5/15/23 | 8/11/23 | 11/14/23 | 3/28/24 | 5/15/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | - | - | -38 | -63.1 | -66.1 | -35.8 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | 0.1100 | 0.0800 | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 0.44 | 0.27 | - | - | 1.07 | 3.71 | 1.06 | 1.08 |
| Capex / Sales | 6.07% | 2.82% | - | - | 74.76% | 709.11% | 330.02% | 257.07% |
| Announcement Date | 9/24/19 | 9/17/20 | 9/21/21 | 5/1/23 | 3/28/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.38
USD
Average target price
2.26
USD
Spread / Average Target
+63.77%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +248.26% | 930M | |
| +43.36% | 54.64B | |
| -5.31% | 39.92B | |
| +37.52% | 38.82B | |
| +14.75% | 26.86B | |
| -12.56% | 26.22B | |
| -22.45% | 18.78B | |
| +25.12% | 12.21B | |
| +0.04% | 12.16B | |
| +26.04% | 11.94B |
- Stock Market
- Equities
- CATX Stock
- Financials Perspective Therapeutics, Inc.
